Micaela Gentile studies kidney disease. Trained in Italy, after her fellowship in kidney disease, she worked at the Translational Transplant Research Center at Mount Sinai, New York, where she collaborated on studies about IgA nephropathy.
Kidneys play an important but understudied role in the body. Their primary role is to remove waste products and extra water, but they also regulate blood pressure, blood cell production, and bone growth. If anything unwanted enters the body, it is the kidneys' job to filter it out. Kidneys today are not as healthy as they were a decade ago; every year, rates of kidney disease rise. Part of this rise is explained by the fact that, as the population lives longer, aging kidneys become more vulnerable. Another part comes from the increased use of medications. As kidneys filter out toxic byproducts of potent medicines, they become strained and less able to perform their normal functions. Stronger medications mean more metabolic waste the kidneys must filter. And chronic illnesses like cancer, diabetes, and hypertension often require drugs that tax the kidneys further. Today, nephrologists often work with oncologists to manage kidney-safe treatment plans.
But medications alone don’t explain the rise. Gentile believes a key part of the answer lies in the immune system. She points to immune system malfunctions driven by chemical exposure and rising autoimmune disorders as another major factor harming the kidneys.
The Fight Against IgA Nephropathy
Gentile's research focuses on one disease, IgA nephropathy, also known as Berger’s disease. It is one of the most common autoimmune kidney disorders: the immune system generates faulty antibodies that clog the kidney’s filters. Previously, most research on this disease focused on its progression and ways to manage symptoms. In recent years, new evidence has highlighted disease pathogenesis, opening opportunities for prevention before symptoms appear.
The prevailing theory behind IgA nephropathy is the "four hit model.” First, immune cells produce an abnormal form of the IgA antibody, missing a key sugar tag (galactose). Second, because of this flaw, the body doesn’t recognize the antibody as its own. It responds by attacking it, forming new antibodies that latch onto the faulty ones like a misfiring army. Third, the immune system amplifies this mistaken identity crisis, producing antibody clusters. Fourth, these clusters clog kidney filters and damage surrounding vessels, eventually leading to kidney failure. Crucially, studies show that kidneys from patients with IgA nephropathy work normally when transplanted into healthy recipients, meaning the defect lies in the immune system, not the kidney itself. Detecting the disease at any of these four hits improves the lives of hundreds of thousands of people.
Her work has already uncovered differences in immune cell populations between healthy individuals and those with the disease. For example, together with other researchers at Mount Sinai, Gentile discovered that patients with IgA nephropathy often have excess natural killer T cells, cells known for killing infected or cancerous cells and producing lots of IgA. This difference may point to potential genetic causes of the disease and a biomarker: patients with more NKT cells may face a greater risk. This discovery also offers hints about where these defective cells may come from. Natural Killer T cells are predominantly in the soft tissue that lines the body's organs, suggesting that the disease may originate in malfunctions in the respiratory or digestive system.
This theory is backed up by potential new treatments like a budesonide steroid, released in the small intestine. Final-stage clinical trials are underway, with FDA approval on the horizon.
Currently, IgA nephropathy can only be diagnosed through invasive testing: urine and blood analyses, along with kidney biopsies.
Microplastics: A New Threat
Gentile says her collaborations with biological supply companies such as Biomatik were vital to these discoveries. She used Biomatik ELISA kits, custom-produced tests that detect antibodies, proteins, and biomolecules in body fluids. These confirmed the presence of secretory IgA in the bloodstream. These companies must work very closely with researchers to ensure the products used in their research deliver accurate results.
Micaela Gentile isn't just looking to cure disorders we already know about; she's trying to forecast and deal with what she thinks might be the next big threat-- microplastics. With the University of Genoa, Gentile has been investigating the effects and accumulation of microplastics in the kidney.
Microplastics are plastic debris smaller than five millimeters. They come from a variety of sources; most commonly, larger plastic debris breaks down into smaller and smaller pieces. In recent years, scientists have detected microplastics in various organs. In one recent study, 26 plastic particles were identified in kidney and urine samples, ranging from 1 to 29 micrometers in size. The most common polymers were polyethylene and polystyrene, often used in food packaging.
This is the first direct evidence of microplastic accumulation in human renal tissues, proving that these particles are not only ingested but may also remain embedded in filtration organs over time.
Of particular concern is their interaction with other pollutants. One major concern is bisphenol A (BPA), an industrial plasticizer widely found in plastics, food packaging, and water bottles.
Dr. Micaela Gentile’s work connects multiple threads of modern medicine, such as immunology, toxicology, and nephrology, and tells one story: our kidneys are struggling like never before. Whether from misfiring immune systems or the invasion of microplastics, the organs responsible for keeping our bodies clean are showing signs of strain.
Her research offers a roadmap forward: early detection, a deeper understanding of immune pathways, and public awareness of the environmental pollutants we carry inside us. But it also offers a warning. The kidneys, more than most organs, reflect the state of our environment. As the global chemical burden increases, their suffering is a sign that our bodies and our planet are absorbing more than they can bear.